Zhang et al. also comprehensively demonstrated that levels of angiogenic factors regulated by HIFs remain elevated in the eyes of patients with diabetes, despite treatment with anti-VEGF therapy, and a novel HIF inhibitor (called “32-134D”) prevents retinal neovascularization in OIR mice and further reduces STZ-induced vascular hyperpermeability without retinal toxicity [112]. The gene discussed is VEGFA; the disease is diabetes mellitus.